GLORIA

GEOMAR Library Ocean Research Information Access

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Neutralizing interferon β antibodies in melanoma patients treated with recombinant and natural interferon β (1994)
    Springer
    Cancer immunology immunotherapy 39 (1994), S. 263-268 
    Details
    ISSN: 1432-0851
    Keywords: Key words: Melanoma – Interferon β– Antibodies – Adjuvant trial
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract. The incidence and clinical significance of therapy-induced neutralizing interferon β (IFNβ) antibodies was studied in a group of 21 melanoma patients treated with natural IFNβ and 7 patients treated with recombinant IFNβ. They were treated subcutaneously with 3×106 IU three times per week in an adjuvant open trial for 24 weeks after surgical removal of all detectable metastases. Of the 21 patients treated with natural IFNβ, 95% developed significant levels of neutralizing antibodies after 24 weeks. In comparison, 28% of the 7 patients treated with recombinant IFNβ developed neutralizing IFNβ antibodies. Cross-reactivity of the antibodies could be demonstrated. Persistence of antibody titers was seen in 80% of the patients 24 weeks after cessation of treatment with natural IFNβ. No correlation between the maximum antibody titers and the antibody persistence after cessation of therapy could be established. We detected a clear correlation between the formation of neutralizing antibodies and the decrease in β2-microglobulin and 2′,5′-oligoadenylate synthetase and therefore the drop in biological activity. In this adjuvant trial there was no difference in relapse rate and time until relapse between antibody-positive and antibody-negative patients. No difference in clinical outcome could be established between the patients treated with natural IFNβ and recombinant IFNβ
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01525990
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Neutralizing interferon β antibodies in melanoma patients treated with recombinant and natural interferon β (1994)
    Springer
    Cancer immunology immunotherapy 39 (1994), S. 263-268 
    Details
    ISSN: 1432-0851
    Keywords: Melanoma ; Interferon β ; Antibodies ; Adjuvant trial
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract The incidence and clinical significance of therapy-induced neutralizing interferon β (IFNß) antibodies was studied in a group of 21 melanoma patients treated with natural IFNß and 7 patients treated with recombinant IFNß. They were treated subcutaneously with 3×106 IU three times per week in an adjuvant open trial for 24 weeks after surgical removal of all detectable metastases. Of the 21 patients treated with natural IFNß, 95% developed significant levels of neutralizing antibodies after 24 weeks. In comparison, 28% of the 7 patients treated with recombinant IFNß developed neutralizing IFNß antibodies. Cross-reactivity of the antibodies could be demonstrated. Persistence of antibody titers was seen in 80% of the patients 24 weeks after cessation of treatment with natural IFNß. No correlation between the maximum antibody titers and the antibody persistence after cessation of therapy could be established. We detected a clear correlation between the formation of neutralizing antibodies and the decrease in β2-microglobulin and 2′,5′-oligoadenylate synthease and therefore the drop in biological activity. In this adjuvant trial there was no difference in relapse rate and time until relapse between antibody-positive and antibody-negative patients. No difference in clinical outcome could be established between the patients treated with natural IFNß and recombinant IFNß.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01525990
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    Stellungnahme und Empfehlungen der Kommission malignes Melanom der Deutschen Dermatologischen Gesellschaft zur Diagnostik, Behandlung und Nachsorge des malignen Melanoms der Haut (1994)
    Springer
    Der Hautarzt 45 (1994), S. 285-291 
    Details
    ISSN: 1432-1173
    Keywords: Schlüsselwörter: Diagnostik – Prognose – Stadieneinteilung – Behandlung – Nachsorge – Malignes Melanom ; Key words: Diagnosis – Prognosis – Classification – Treatment – Follow-up – Melanoma
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Summary. The Melanoma Committee of the German Dermatological Society has prepared this position paper on prognostic factors, classification and clinical staging of cutaneous malignant melanoma and has recommended guidelines for diagnosis, treatment and follow-up. The aim is to achieve a consensus procedure for dealing with this tumour.
    Notes: Zusammenfassung. Die Kommission malignes Melanom der Deutschen Dermatologischen Gesellschaft hat zur Frage der prognostischen Faktoren der Klassifikation und der klinischen Stadieneinteilung des malignen Melanoms der Haut Stellung bezogen und für den deutschsprachigen Raum ein einheitliches Vorgehen zur Diagnose, Therapie und Nachsorge empfohlen.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/s001050050071
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...